| Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan T Furuta, EM El–Omar, F Xiao, N Shirai, M Takashima, H Sugimurra Gastroenterology 123 (1), 92-105, 2002 | 483 | 2002 |
| Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer T Furuta, K Ohashi, T Kamata, M Takashima, K Kosuge, T Kawasaki, ... Annals of internal medicine 129 (12), 1027-1030, 1998 | 449 | 1998 |
| Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies T Furuta, N Shirai, M Sugimoto, A Nakamura, A Hishida, T Ishizaki Drug metabolism and pharmacokinetics 20 (3), 153-167, 2005 | 432 | 2005 |
| CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans T Furuta, K Ohashi, K Kosuge, XJ Zhao, M Takashima, M Kimura, ... Clinical Pharmacology & Therapeutics 65 (5), 552-561, 1999 | 346 | 1999 |
| Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin T Furuta, N Shirai, M Takashima, F Xiao, H Hanai, H Sugimura, K Ohashi, ... Clinical Pharmacology & Therapeutics 69 (3), 158-168, 2001 | 317 | 2001 |
| Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH N Shirai, T Furuta, Y Moriyama, H Okochi, K Kobayashi, M Takashima, ... Alimentary pharmacology & therapeutics 15 (12), 1929-1937, 2001 | 284 | 2001 |
| Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition M Kato, H Ota, M Okuda, S Kikuchi, K Satoh, T Shimoyama, H Suzuki, ... Helicobacter 24 (4), e12597, 2019 | 263 | 2019 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing JJ Lima, CD Thomas, J Barbarino, Z Desta, SL Van Driest, N El Rouby, ... Clinical Pharmacology & Therapeutics 109 (6), 1417-1423, 2021 | 233 | 2021 |
| Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study H Hanai, F Watanabe, K Takeuchi, T Iida, M Yamada, Y Iwaoka, ... Clinical Gastroenterology and Hepatology 1 (1), 28-35, 2003 | 223 | 2003 |
| Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole T Furuta, N Shirai, F Watanabe, S Honda, K Takeuchi, T Iida, Y Sato, ... Clinical Pharmacology & Therapeutics 72 (4), 453-460, 2002 | 223 | 2002 |
| Pharmacogenomics‐based Tailored Versus Standard Therapeutic Regimen for Eradication of H. pylori T Furuta, N Shirai, M Kodaira, M Sugimoto, A Nogaki, S Kuriyama, ... Clinical Pharmacology & Therapeutics 81 (4), 521-528, 2007 | 222 | 2007 |
| Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP 2C19 genotype T Kagami, S Sahara, H Ichikawa, T Uotani, M Yamade, M Sugimoto, ... Alimentary Pharmacology & Therapeutics 43 (10), 1048-1059, 2016 | 217 | 2016 |
| A deficiency of gastric interstitial cells of Cajal accompanied by decreased expression of neuronal nitric oxide synthase and substance P in patients with type 2 diabetes mellitus H Iwasaki, M Kajimura, S Osawa, S Kanaoka, T Furuta, M Ikuma, ... Journal of gastroenterology 41, 1076-1087, 2006 | 217 | 2006 |
| Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer M Sugimoto, Y Yamaoka, T Furuta World journal of gastroenterology: WJG 16 (10), 1188, 2010 | 210 | 2010 |
| The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects K Umemura, T Furuta, K Kondo Journal of Thrombosis and Haemostasis 6 (8), 1439-1441, 2008 | 210 | 2008 |
| Effects of Helicobacter pyloriinfection on gastric acid secretion and serum gastrin levels in Mongolian gerbils M Takashima, T Furuta, H Hanai, H Sugimura, E Kaneko Gut 48 (6), 765-773, 2001 | 210 | 2001 |
| Different effects of polymorphisms of tumor necrosis factor‐alpha and interleukin‐1 beta on development of peptic ulcer and gastric cancer M Sugimoto, T Furuta, N Shirai, A Nakamura, F Xiao, M Kajimura, ... Journal of gastroenterology and hepatology 22 (1), 51-59, 2007 | 199 | 2007 |
| Evidence that the Degree and Duration of Acid Suppression are Related to Helicobacter pylori Eradication by Triple Therapy M Sugimoto, T Furuta, N Shirai, C Kodaira, M Nishino, M Ikuma, T Ishizaki, ... Helicobacter 12 (4), 317-323, 2007 | 196 | 2007 |
| Pharmacogenomics of proton pump inhibitors T Furuta, N Shirai, M Sugimoto, K Ohashi, T Ishizaki Pharmacogenomics 5 (2), 181-202, 2004 | 187 | 2004 |
| Pharmacologic aspects of eradication therapy for Helicobacter pylori infection T Furuta, DY Graham Gastroenterology Clinics 39 (3), 465-480, 2010 | 182 | 2010 |
